158654-74-1 Usage
Uses
Used in Organic Synthesis:
Isoquinoline, 5-(bromomethyl)(9CI) is used as a building block for the synthesis of various organic compounds. Its bromine substituent imparts specific properties and reactivity, making it valuable in the development of new chemical products.
Used in Medicinal Chemistry:
Isoquinoline, 5-(bromomethyl)(9CI) is used as a key intermediate in the synthesis of pharmaceutical agents. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Pharmaceutical Product Development:
Isoquinoline, 5-(bromomethyl)(9CI) is used as a starting material for the creation of novel pharmaceutical products. Its reactivity and bromine substituent enable the design of innovative compounds with improved therapeutic properties and efficacy.
Check Digit Verification of cas no
The CAS Registry Mumber 158654-74-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,8,6,5 and 4 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 158654-74:
(8*1)+(7*5)+(6*8)+(5*6)+(4*5)+(3*4)+(2*7)+(1*4)=171
171 % 10 = 1
So 158654-74-1 is a valid CAS Registry Number.
158654-74-1Relevant academic research and scientific papers
THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION
-
, (2019/02/13)
Disclosed herein are compounds of formula I: or a salt thereof and compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods for treating or preventing a bacterial infection in an animal comprising administering to the animal a compound of formula I or a pharmaceutically acceptable salt thereof, alone or in combination with a bacterial efflux pump inhibitor.
SUBSTITUTED PYRIDINONES
-
, (2008/06/13)
Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.
